ReviewJournal of innate immunity2015
Activation of Type I and Type III Interferons in Chronic Hepatitis C.
Review in Journal of innate immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Downregulation of SOCS1 increases interferon-induced ISGylation during differentiation of induced-pluripotent stem cells to hepatocytes.JHEP reports : innovation in hepatology · 2022Article
- HepaticInternational journal of molecular sciences · 2021Article
- Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma.World journal of gastroenterology · 2020Review
- COVID-19: Possible Impact of the Genetic Background in IFNL Genes on Disease Outcomes.Journal of innate immunity · 2020Article
- Interferon-λ orchestrates innate and adaptive mucosal immune responses.Nature reviews. Immunology · 2019Review
- Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.Journal of neurology · 2019Observational
- The impact of chronic hepatitis C infection on cholesterol metabolism in PBMCs is associated with microRNA-146a expression.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2017Article
- Interferon Lambda: Modulating Immunity in Infectious Diseases.Frontiers in immunology · 2017Review
- Applications of Replicating-Competent Reporter-Expressing Viruses in Diagnostic and Molecular Virology.Viruses · 2016Review
- On PAMPs and DAMPs.Journal of innate immunity · 2016Article
- Inflammatory status in human hepatic cirrhosis.World journal of gastroenterology · 2015Review
- Interferon-λ: Inters Ferocity or Inter-Ferocities?Journal of innate immunity · 2015Article
- Article
- The role of microRNAs in enteroviral infections.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection with hepatitis C virus (HCV) results in chronic and progressive liver disease. Persistency rates add up to 85%. Despite recognition of the virus by the human host in peripheral blood and in the liver, immune response appears to be ineffective in clearing infection. The ability to spontaneously eradicate the virus as well as the outcome of infection upon therapy with human recombinant interferon-α (IFN-α) was found to correlate most closely with genetic variations within the region encoding the IFN-λ genes, as revealed by genome-wide association studies on main ethnic populations in 2009. This review summarizes the induction of type I and type III IFN genes and their effectors, the IFN-stimulated genes. It focusses on the in vivo situation in chronic HCV infection in man both in the peripheral blood compartment and in the liver. It also addresses the impact of genetic polymorphisms in the region of type III IFN genes on their activation. Finally, it discusses how antiviral drugs (i.e. IFN-α, ribavirin and the direct-acting antivirals) may complementarily control the activation of endogenous IFNs and succeed in combatting infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.